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Stevens–Johnson syndrome and toxic epidermal necrolysis are severe cutaneous adverse reactions that are of
major concern because of high mortality rates. On the basis of data collected in the RegiSCAR study, the aim was
to assess risk factors (including modalities of patient management) for mortality, regardless of the cause, up to
1 year after the reaction. Within this cohort, the mortality rate was 23% (95% confidence interval (CI) 19–27%) at
6 weeks and 34% (95% CI 30–39%) at 1 year. Severity of reaction was a risk factor for mortality only in the first 90
days after onset, whereas serious comorbidities and age influenced mortality beyond 90 days and up to 1 year
after onset of reaction. The risk of death for patients with identified drug cause was borderline lower than for
patients with a reaction of unknown cause (hazard ratio 0.66, 95% CI 0.45–0.96). The study could not provide
conclusive evidence regarding patient management. This large-scale population-based follow-up study of such
patients confirmed high in-hospital mortality and revealed a remarkable number of deaths after discharge, which
could mainly be attributed to severe comorbidities and older age, whereas the impact of severity of reaction on
the risk of death was limited to the first few weeks.
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INTRODUCTION
Stevens–Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are rare severe cutaneous adverse reactions
(SCAR) mainly induced by drugs (Valeyrie-Allanore and
Roujeau, 2008; Mockenhaupt, 2009; Breathnach, 2010).
Both are characterized by large areas of detachment of
necrotic epidermis and erosions of mucous membranes and
are thus considered as one entity differing only in the amount
of skin detachment related to the body surface area: SJS refers
to patients with up to 10% detachment, TEN to patients with
more than 30% detachment, and the overlap form to
intermediate detachment (Bastuji-Garin and Rzany et al.,
1993). SJS/TEN are of major concern because of severe
morbidity and high mortality rates reported from less than
10% in SJS patients to more than 40% in TEN patients (overall
20–25%) (Valeyrie-Allanore and Roujeau, 2008; Breathnach,
2010). Because of the rareness of the reaction (Europe: 1.5–2
patients/year/million people), knowledge is often derived from
case reports or small cohorts, leaving several questions
unanswered (Naldi et al., 1990; Roujeau et al., 1990; Rzany
et al., 1996). Presumably for the same reason, no treatment
benefit could be demonstrated until now (Endorf et al., 2008;
Valeyrie-Allanore and Roujeau, 2008; Lissia et al., 2010).
To decrease mortality, prompt withdrawal of any potentially
causative drug and early transfer to burn units or any
specialized units have been suggested (McGee and Munster,
1998; Garcia-Doval et al., 2000; Schulz et al., 2000;
Palmieri et al., 2002). However, these recommendations are
based on retrospective data of patients treated in secondary or
tertiary referral centers. Although referral to such centers
provides access to specific facilities, studies are prone to
referral bias.
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With respect to risk factors for death, a prognostic score for
in-hospital mortality (SCORTEN) has been developed and
validated (Bastuji-Garin et al., 2000; Sekula et al., 2011).
The score simply adds seven risk indicators including age
X40 years, recent malignancy, detached body surface area
X10%, and few abnormal laboratory values. As in several
other studies assessing risk factors for death, the time of death
and deaths after discharge were not taken into account
(Bastuji-Garin and Zahedi et al., 1993; Schulz et al., 2000;
Gravante et al., 2007; Dorafshar et al., 2008). The latter might
contribute substantial numbers (Haber et al., 2005; Oplatek
et al., 2006). Late transfer to burn units and high SCORTEN
values were reported as risk factors for death after discharge
(Oplatek et al., 2006).
RegiSCAR (International Registry of Severe Cutaneous
Adverse Reactions to drugs) is an ongoing registry of different
types of SCAR including SJS/TEN. Besides clinically relevant
information before the reaction, as well as information on the
course and treatment of the reaction, patients included in
RegiSCAR (January 2003–March 2007) were additionally
asked for consent to answer a standardized questionnaire
1 year after the onset of the reaction. The aims of this systematic
population-based follow-up study on a large cohort of SJS/TEN
patients were to investigate their survival status, the presence
of sequelae, and quality of life after a defined period of time.
We focused here on the analysis of mortality, regardless of
the cause, up to 1 year after the reaction and potential risk
factors obtained at baseline. As physicians so far assumed that
SJS/TEN only had an impact on death in the first few weeks
after onset of the reaction, we were, especially, interested
to assess time-varying impact of risk factors. In addition,
we investigated whether the risk for death varied depending
on drugs responsible for the reactions and on modalities of
patient management (treating unit, delayed transferal, therapy).
RESULTS
Table 1 presents a description of the follow-up cohort and of
patients who did not consent, including previously suspected
risk factors for death. The comparison of their distributions
revealed P-values above 0.05 for all listed variables except
country (0.02).
Within 1 year, 149 deaths of any cause were observed.
At day 42, the mortality rate was 23% (95% confidence interval
(CI) 19–27%). It increased to 28% (95% CI 23–32%) at day 90
and to 34% (95% CI 30–39%) at 1 year. Figure 1a displays the
estimated survival curve over all patients, whereas Figure 1b–d
show the curves stratified by previously suspected risk factors:
age (cutoff point: median age), severity of the reaction, and
recent malignancy. When distinguishing patients by severity,
the mortality rates at 6 weeks were 12% (95% CI 8–16%) for
SJS, 29% (95% CI 22–36%) for SJS/TEN overlap, and 46% (95%
CI 33–57%) for TEN, whereas the corresponding numbers at
1 year were 24% (95% CI 18–29%) for SJS, 43% (95% CI 35–
50%) for SJS/TEN overlap, and 49% (95% CI 36–60%) for TEN.
A: main analysis
The variables age, severity of the reaction, severe liver
disorder, severe kidney disorder, recent malignancy, and
recent infection were selected for the regression of survival
times. The assessment of these variables within three time
periods (0–42, 42–90, and 90–365 days) indicated time-
varying effects for severity of the reaction and recent malig-
nancy (Table 2: models 1a–c). Comprehensive analysis (0–365
days) revealed that the effect of the most severe reaction type
(TEN) was limited to the first 90 days, whereas the effect of
recent malignancy intensified during the year after the reaction
(Table 2: model 2, Figure 2).
Focusing on patients who were still alive at day 90 (n¼299)
illustrates the change in the hierarchy of prognostic factors
after 90 days: the conditional mortality rate for 107 patients
with a serious comorbidity (severe liver/kidney disorder,
recent malignancy) or of older age (470) was 24% (95% CI
15–32%) at 1 year, whereas it was 1.6% (95% CI 0.0–3.4%)
for the remaining 192 patients with no serious comorbidity
and age below 70 years. The risk of dying after 90 days was
thus higher for the former group of patients (HR 18, 95% CI
5.4–61). In contrast, the risk estimate for severity of the
reaction (SJS/TEN overlap, TEN versus SJS) was insignificant
(HR 1.5, 95% CI 0.7–3.3) after 90 days.
Results did not change with different methods for dealing
with missing values in the variables (data not shown).
Table 1. Description of population
Frequency and percentage if not
stated otherwise (based on
patients with available
information)
Follow-up
cohort,
n¼ 460
Patients not included
in the follow-up
cohort, n¼ 49
Country 123 (27%) 20 (41%)
France
Germany 270 (59%) 19 (39%)
Other countries1 67 (15%) 10 (20%)
Gender: male 203 (44%) 22 (45%)
Age (in years) mean, SD 51.4 (22.8) 50.1 (25.5)
Severe liver disorder2 51 (11%) 4 (8%)
Severe kidney disorder2 56 (12%) 7 (14%)
Collagen–vascular disorder2 27 (6%) 1 (2%)
Recent malignancy2 72 (16%) 10 (21%)
HIV infection 20 (9%) 2 (8%)
Recent infection2 78 (18%) 5 (13%)
Recent radiation therapy 36 (8%) 5 (10%)
Prior steroid use 96 (21%) 11 (22%)
Development of reaction, in-hospital 131 (28%) 12 (24%)
Severity of reaction
SJS 228 (50%) 26 (53%)
SJS/TEN overlap 161 (35%) 15 (31%)
TEN 71 (15%) 8 (16%)
Outcome death, in-hospital 114 (25%) 11 (22%)
Abbreviations: SJS, Stevens–Johnson syndrome; TEN, toxic epidermal
necrolysis.
1Other countries: Italy (37), the Netherlands (19), Israel (17), Austria (4).
2See Supplementary Table S2 online for a description of variables.
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The inclusion of severity information as time-varying
in the final survival model (excluding step function for
TEN) had no effect on the estimates of the HRs of other
variables except severity itself, which slightly increased:
SJS/TEN overlap, 3.4 (95% CI 2.3–5.0); TEN, 10.5 (95%
CI 6.5–17.0).
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Figure 1. Survival curves. Median age was used as cut-point to define age groups.
Table 2. Multivariable Cox regression
A: main analysis (n¼460)
Model 1a,
0–42 days
Model 1b,
42–90 days
Model 1c,
90–365 days
Model 2,
0–365 days
No. of observed events 104 18 27 149
Based on a simply imputed data set HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Age (in years) 1.04 (1.03–1.05) 1.04 (1.02–1.06) 1.04 (1.02–1.07) 1.04 (1.03–1.05)
Severity of skin reaction
SJS 1 1 1 1
SJS/TEN overlap 2.6 (1.6–4.2) 2.4 (1.3–4.5) 2.1 (0.9–5.0) 2.4 (1.7–3.5)
TEN 7.7 (4.5–13.1) 2.1 (0.5–9.4) 0 (0) 7.7 (4.8–12.4)1
Severe liver disorder2 3.1 (1.9–4.9) 4.2 (1.9–9.5) 4.0 (1.3–12.9) 3.4 (2.3–5.1)
Severe kidney disorder2 2.4 (1.5–3.7) 1.3 (0.6–3.0) 1.2 (0.4–3.5) 2.0 (1.4–3.0)
Recent malignancy2 1.2 (0.7–2.0) 5.5 (2.9–10.3) 8.7 (3.9–19.4) 1.15 (1.09–1.20)3
Recent infection2 1.5 (0.9–2.3) 2.0 (1.0–3.9) 1.3 (0.5–3.4) 1.6 (1.1–2.3)
Abbreviations: CI, confidence interval; HR, hazard ratio; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.
Dark gray cells correspond to insignificant HRs; time-varying HRs are marked in bold.
1See Supplementary Table S2 online for a description of variables.
2Functional form of effect for TEN: ln(HR)¼2.04*I(timep90).
3Functional presentation.
Form of effect for recent malignancy: ln(HR)¼ 0.14*sqrt(time) further comment: see Figure 2 for a graphical presentation of time-varying HRs.
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B analysis: impact of drug cause
For 453 patients (98%), drug information was available. One
or more drugs were assessed as probably or very probably
responsible in 305 patients (67%) (Table 3B). In 69% of these
patients, the identified medication(s) belonged to the ‘‘strongly
associated’’ drug category. Compared with patients with no
identified drug, patients with at least one identified drug had a
borderline significant lower mortality (Table 3B).
C analysis: patient management
About half of the patients (55%) were treated on a unit that
provides special equipment for the treatment of SJS/TEN
patients. However, their practical experience is often with
1–2 patients/year, rather limited. By focusing on units
that treated 5 or more patients during the study period, 150
patients (34%) were treated in a SJS/TEN-specialized unit
(Supplementary Table S1 online). Its effect on mortality, as
well as the estimated HR for the delay between hospitalization
(any unit) and admission to a SJS/TEN-specialized unit (both
restricted to transfers within first seven days after admission),
revealed no significant associations (Table 3C).
Patients received many different immunomodulating treat-
ments (Supplementary Table S1 online). In all, 20% of the
patients (n¼ 87) were already treated with any immunomo-
dulating drug (mainly corticosteroids) before the onset of the
reaction because of an underlying condition. In 26 of the 87
patients (30%), the therapy was discontinued under the
reaction or only continued without any change in administra-
tion and thus neglected in the analysis of medications
administered to treat. In particular, corticosteroid use was
very country dependent. The majority of patients came from
Germany, where the corticosteroid use is the treatment of
choice for SJS and TEN, explaining its high prevalence in our
study. In France, on the other hand, only a quarter of the
patients received corticosteroids. In addition, French patients
received them at a lower dosage than German patients
(median maximum daily dosage: 75 mg in France, 250 mg in
Germany). In regression analysis, single effects for different
therapy types (in comparison to supportive therapy only) were
insignificant and heterogeneous (Table 3C).
DISCUSSION
A large-scale population-based 1-year follow-up study of SJS/
TEN patients was conducted—a study that, to our knowledge,
has not been reported previously. The survival status of 460
patients included in different countries (France 27%, Germany
59%, other countries 15%) and with a confirmed diagnosis of
SJS/TEN was assessed about 1 year after their reaction.
Within this cohort, the 6-week mortality rate was 23%
(95% CI 19–27%), which was in agreement with prior reports
of in-hospital mortality (Valeyrie-Allanore and Roujeau, 2008;
Breathnach, 2010). However, we also observed a remarkable
number of deaths among 6-week survivors, with a death rate
(6 weeks–1 year) of 14% (95% CI 10–18%). Consequently, the
overall mortality at 1 year after the occurrence of SJS/TEN was
34% (95% CI 30–39%). When distinguishing patients
by severity, the mortality rate at 1 year was 24% (95% CI
18–29%) for SJS, 43% (95% CI 35–50%) for SJS/TEN overlap,
and 49% (95% CI 36–60%) for TEN. These results confirm and
extend those of two prior studies that had also reported on
deaths after discharge (Haber et al., 2005: 16% of discharged
patients; Oplatek et al., 2006: 33% of discharged patients).
We found several factors having an impact on mortality:
age, severity of reaction, recent malignancy, and preexisting
severe kidney or liver disorder, as well as recent infection.
Among them, severe liver or kidney disorders were detected as
independent risk factors for death, which were not known
earlier. However, they are components of the APACHE II (part:
chronic health classification), which is a validated severity
scoring system applied to severely ill patients, and that was
found as a risk factor for in-hospital death in patients with TEN
(Knaus et al., 1985; Palmieri et al., 2002). Furthermore, the
analysis revealed recent infection as an independent risk factor
for death. So far, infections were not reported from other
studies assessing the risk for death. Their role in the induction
of the reaction is discussed (Valeyrie-Allanore and Roujeau,
2008; Mockenhaupt, 2009). All other factors are part
of the SCORTEN, a prognostic score for in-hospital
mortality (Bastuji-Garin et al., 2000). As Oplatek et al.
(2006) reported that higher SCORTEN values were also
considered as risk factors for death after discharge, the
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Figure 2. Graphical representation of the selected function for the time-varying impact of recent malignancy (left) and the most severe reaction type (TEN;
right) on mortality.
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present results support those findings including the relevance
of SCORTEN itself.
The evaluation of the time-varying impact of selected risk
factors expectedly revealed a decreasing effect of severity of
the reaction, especially of TEN. The arbitrarily chosen cutoff
point for the step function at day 90 is supported by the fact that
none of the TEN patients (n¼31 still alive at day 90) sub-
sequently died, with 28 patients still under observation at
1 year. In contrast, recent malignancy had basically no effect
in the first 42 days, but a strikingly increased effect in the later
period (90–365 days: HR 8.7; 95% CI 3.9–19.4). Published
results are rather dissimilar with respect to malignancies being a
risk factor for in-hospital death. Although some authors presented
significant results, others did not detect it or presented only a
borderline significant result (Bastuji-Garin et al., 2000; Palmieri
et al., 2002; Gravante et al., 2007; Dorafshar et al., 2008).
During the later follow-up period (90–365 days), the
survival did not substantially decrease beyond 3 months
(conditional mortality rate 1.6% (95% CI 0.0–3.4%)) among
SJS/TEN patients with no serious comorbidity and of younger
age. In contrast, a quarter of patients with a serious comor-
bidity or of older age who survived the first 3 months died
during the remaining year. As there was no evidence that the
initial severity of the reaction had a role during the later
period, it can be assumed that underlying diseases or age
mainly have caused later deaths in this cohort.
Most patients (67%) had reactions (very) probably caused
by various drugs. The comparison of patients with at least one
drug identified versus patients with no drug identified reached
borderline significance with higher risk for death in patients
with no drug identified. However, as the latter cases are
heterogenous, some being probably drug induced but with
exposure to so many medications that none clearly emerged
and others possibly related to a non-identified infectious
cause, we are not able to further explore the possible reasons
for a worse prognosis.
Table 3. Additional regression analyses within subgroups
Frequency (percentage) Adjusted1 HR (95% CI)
B: Drugs probably or very probably responsible for SJS/TEN (n¼453)
Drug identified as responsible
No 148 (33%) 1
Yes (at least one) 305 (67%) 0.66 (0.45–0.96)
Drug identified as responsible (categorized)
No 148 (33%) 1
Strongly associated drug2
Allopurinol 78 (17%) 0.81 (0.51–1.29)
Antiepileptic drug 86 (19%) 0.66 (0.40–1.10)
Other strongly associated drug 53 (12%) 0.77 (0.42–1.43)
Other drug 116 (26%) 0.84 (0.55–1.28)
C: Treating unit, delay in transferral, and therapies (n¼ 442)
Treatment at SJS/TEN-specialized3 unit when transferred within first seven days after admission
No 107 (24%) 1
Yes 335 (76%) 0.87 (0.60–1.27)
Delay between hospitalization4 and admission to SJS/TEN-specialized3 unit within first seven days
Delay (for each further day) 1.04 (0.96–1.11)
Therapies (taking start of therapy into account)
Supportive therapy only 97 (22%) 1
Corticosteroids 317 (72%) 1.3 (0.8–1.9)
Intravenous immunoglobulins 81 (18%) 1.3 (0.9–2.0)
Any other immunomodulating drug5 24 (5%) 0.26 (0.06–1.06)
Abbreviations: CI, confidence interval; HR, hazard ratio; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.
1For each of the 5 listed items, a separate Cox model was fitted adjusted for variables included in model 2 (see Table 2).
2Strongly associated drugs: allopurinol, antiepileptic drugs (carbamazepine, lamotrigine, phenobarbital, phenytoin), other strongly associated drugs (anti-
infective sulfonamides, sulfasalazine, nevirapine, oxicam nonsteroidal anti-inflammatory drugs).
3See Supplementary Table S3 online for a description of variable definition for SJS/TEN-specialized unit.
4Date of admission to hospital (any unit), if onset before admission, otherwise date of definite onset (first definite sign) was used to determine delay in transferal
to SJS/TEN-specialized unit.
5Any other immunomodulating drug: ciclosporin (19), daclizumabþ etanercept (1), hydroxylcarbamide (1), infliximab (3).
Further comment: likelihood ratio test comparing model 2 with model 2 plus therapies: P¼ 0.04.
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With respect to patient management, many patients were
treated in units that were well equipped but often had limited
practical experience. Although our analysis focused on more
experienced centers, neither treatment in such a unit nor early
transfer showed any significant impact on mortality in this
cohort. In spite of our results, we believe that a decrease in the
mortality can be obtained with an improved referral policy,
leading to the emergence of a limited number of reference
centers for SJS/TEN.
The analysis of the impact of different immunomodulating
therapies on mortality provided insignificant effect estimates in
comparison with supportive therapy only. However, owing to
the facts that patients were treated in different ways, that many
were already immunomodulated at the beginning of the
reaction, and that there was a lack of detailed information
about the course of the reaction (e.g., degree of progression,
complications), we consider that the current analysis may
have a limited validity.
Remarkably, most patients received corticosteroids at some
point after the start of the reaction—a therapy that is still
controversial (Valeyrie-Allanore and Roujeau, 2008).
However, the limited data collected on treatment do not
allow for fine analyses, but anyway the global effect of
corticosteroids in comparison with supportive therapy only
is not significant, as it is for intravenous immunoglobulins.
For other immunomodulating drugs in comparison with
supportive therapy only, the effect estimate indicates a
treatment benefit (HR 0.26, 95% CI 0.06–1.06), but sizes of
both groups additionally limit the power of comparison.
Finally, a limitation of this study is that this analysis deals
with patients who were mainly included in France and
Germany (85%). Thus, presented results may only apply for
Europe, at least in part.
To conclude, we observed not only a remarkable number of
deaths during the first weeks after onset of the reaction, but
also a sizeable number of deaths after discharge. Our findings
suggest that the severity of reaction is one of the major risk
factors for death in the first few weeks and has no impact on
mortality after about 3 months. Later deaths are associated
with severe comorbidities and older age. We therefore suggest
that death rates for SJS/TEN should be evaluated at 3 months
rather than at 6 weeks.
With one out of four patients dying in the first few weeks
after onset, SJS/TEN is actually the most severe adverse drug
reaction. For comparison, anaphylactic shock is associated
with death rates below 10%, and even acute liver failure
mortality decreased below 30%, with easier access to liver
transplantations (Helbling et al., 2004; Bernal et al., 2010). In
the population of the European Union with about 500 million
inhabitants, about 1,000 cases of SJS/TEN are expected to
occur, with about 250 directly associated deaths each year.
MATERIALS AND METHODS
RegiSCAR
RegiSCAR, started in 2003, is an ongoing pharmaco-epidemiologic
study with collection of biological samples on SCAR (including SJS/
TEN) that is conducted in accordance with the Declaration of
Helsinki Principles. After having obtained ethics committee approval,
investigators from Austria, France, Germany, Israel, Italy, and the
Netherlands included patients into the present cohort who were
admitted to a contributing hospital with suspicion of having
SCAR. A written consent was obtained from each patient included
in the study.
A trained interviewer (medical professional) collects clinical data
by talking directly to the patient, treating physicians, or family
members using a reaction-specific, standardized questionnaire.
An expert committee blinded for drugs and other exposures (i.e.,
infections, comorbidities) reviews all cases based on clinical data,
histopathology, and photographs. Each potential case of SJS/TEN is
validated according to a standardized process as definite, probable, or
possible case of SJS/TEN, or is excluded owing to another diagnosis
(Bastuji-Garin and Rzany et al., 1993). In addition, the date of onset of
the reaction is determined using a standardized algorithm.
From January 2003 to March 2007, the diagnosis of SJS/TEN was
confirmed as probable or definite in 509 patients included in
RegiSCAR (Figure 3); thereof 460 consented to participate in the
follow-up study.
Further details on methods and results of RegiSCAR are given
elsewhere (e.g., Genin et al., 2011).
Statistical methods
Fisher’s exact test for categorical variables and Wilcoxon test for
continuous variables were used for comparing the characteristics of
patients who did and did not consent to the follow-up study.
Although some of the questionnaires were answered after some
delay, the analysis was restricted to the period from disease onset
(day 0) until 365 days after the reaction. The completeness of the
follow-up for this period was estimated as 86% (Clark et al., 2002).
A: main analysis (n¼ 460)
Potential risk factors for death, available within 4 weeks before the
reaction, were preselected on clinical relevance (see Supplementary
Table S2 online for details). Survival methods accounting for right
censoring and left truncation were applied to assess their effects in
terms of hazard ratios (HRs) (Klein and Moeschberger, 2005). For
variable selection, the multivariable fractional polynomial (m.f.p.)
approach was used with backward elimination (significance level for
staying in model¼ 0.05) (Royston and Sauerbrei, 2008). Multivariable
Cox regression model allowing time-varying HRs between predefined
periods (0–42 days, 42–90 days, and 90–365 days) were fitted on the
basis of the selected m.f.p. model. Furthermore, an extension of
the m.f.p. approach was applied to assess the functional form of
possible time-varying effects of selected variables over the whole year
(forward selection, significance level for entry in model¼ 0.05)
(Sauerbrei et al., 2007). The resulting model was checked afterward
for possible simplifications.
Data on demographics and severity of the reaction were complete;
other baseline variables (except HIV status) had missing values, with a
percentage of up to 5%. A patient was considered as not infected with
HIV as long as no positive test result was available. As 400 patients
(87%) had complete information on all potential risk factors, we
imputed missing values using simple algorithms based on observed
distributions. The final model was then checked in a complete
case analysis and by using multiple imputations (10 times) of selected
variables. Preselected variables were all observable at baseline
(¼ onset), except severity of the reaction, which depended on the
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maximum skin detachment seen several days after onset of the
reaction (median: 8 days after onset, range: 0–35). As a further
sensitivity analysis, we thus assessed the final model by letting
severity depend on time. In the absence of detailed information on
the course, each patient was assumed to have started the reaction
with minimum severity (SJS) and switched to the final severity at the
time of maximum skin detachment.
B analysis: impact of drug cause (n¼ 453)
To assess whether drugs probably or very probably responsible
for SJS/TEN (based on the ALDEN algorithm; Sassolas et al., 2010)
have a different impact on mortality, patients without identified drug
cause and with identified drug cause were distinguished. The latter
group was further divided in allopurinol, antiepileptic drugs
(carbamazepine, lamotrigine, phenobarbital, phenytoin), any other
strongly associated drug (including anti-infective sulfonamides, sul-
fasalazine, nevirapine, and oxicam nonsteroidal anti-inflammatory
drugs), and any other drug not strongly associated. The grouping was
chosen in dependence on drug notoriety and the great diversity of
observed drugs responsible for reactions. To adjust for other relevant
factors, variables were added to the final survival model.
C analysis: patient management (n¼ 442)
Different treating units were categorized: SJS/TEN-specialized unit,
dermatologic unit, and any other unit (see Supplementary Table S3
online for details). To assess whether treatment in a SJS/TEN-
specialized unit (considering the date of transfer) or whether the
delay between hospitalization (for patients already hospitalized at
onset, date of first definite sign was used instead) and admission to a
SJS/TEN-specialized unit (both restricted to transfers within first seven
days after admission) had any impact on survival, we separately
added these variables to the final survival model.
Any immunomodulating therapy that was administered during the
reaction was considered, unless if already administered before the
onset of the reaction and then either withdrawn or further adminis-
tered without any increase in dosage or frequency. The different
therapies (taking their start into account) were added to the final
survival model to assess their impact on mortality. Fifteen out of 442
patients were also included in an open trial to assess the treatment
effect of ciclosporin (Valeyrie-Allanore et al., 2010).
For statistical analysis, software packages SAS release 9.2
(SAS Institute Inc., Cary, NC) and STATA release 11.0 (StataCorp
LP, College Station, TX) were used.
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